Across TCGA pan-cancer cohorts, TCEAL9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TCEAL9 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TCEAL9 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TCEAL9 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where TCEAL9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.609	0.338	.003	26	view →
LSCC	DFS	Quartile	II,III,IV	0.361	0.838	.013	6	view →
LUAD	DFS	Median	II,III,IV	0.185	0.739	.038	3	view →
CCRCC	DFS	Tertile	All	0.540	0.915	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TCEAL9 tumor-vs-normal RNA expression · all TCEAL9 data types